Evaluation of the Efficacy and Safety of the Conversion From a Calcineurin Inhibitor to an Everolimus-Based Therapy in Maintenance Renal Transplant Patients

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2148-2150

  Sanchez Fructuoso A ^a   Ruiz San Millan J C ^a   Calvo, N ^a   Rodrigo, E ^a   Moreno, M A ^a   Cotorruelo, J ^a   Conesa, J ^a   Gomez Alamillo C ^a   Arias, M ^a   Barrientos, A ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEINURIA;

CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SAFETY; SIROLIMUS; TREATMENT OUTCOME;

EID: 34548782709     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.030     Document Type: Article

References (10)

1. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22
2. Mota A., Arias M., Taskinen E., et al. Sirolimus- based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 Years. Am J Transplant 4 (2004) 953
3. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 3 (2005) 352 1317
4. Sanchez-Fructuoso A., Conesa J., Perez Flores I., et al. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 38 (2006) 2451
5. Diekmann F., and Campistol J.M. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21 (2006) 562
6. Nashan B. Review of the prolipheration inhibitor everolimus. Expert Opin Investig Drugs 11 (2002) 1845
7. Lutz J., Zou H., Liu S., et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76 (2003) 508
8. Bruns C.J., Koehl G.E., Guba M., et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10 (2004) 2109
9. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2005) 581
10. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883